188 related articles for article (PubMed ID: 36751044)
21. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
22. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
23. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
25. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
[TBL] [Abstract][Full Text] [Related]
26. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
27. Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study.
Miyazaki T; Watanabe K; Kojima K; Koshiba R; Fujimoto K; Sato T; Kawai M; Kamikozuru K; Yokoyama Y; Hida N; Nakamura S
Digestion; 2020; 101(1):53-59. PubMed ID: 31722356
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
[TBL] [Abstract][Full Text] [Related]
29. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
30. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
[TBL] [Abstract][Full Text] [Related]
31. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort.
Kubesch A; Rueter L; Farrag K; Krause T; Stienecker K; Hausmann J; Filmann N; Dignass A; Stein J; Blumenstein I
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817134
[No Abstract] [Full Text] [Related]
32. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Johnson AM; Barsky M; Ahmed W; Zullow S; Galati J; Jairath V; Narula N; Peerani F; Click BH; Coburn ES; Dang TT; Gold S; Agrawal M; Garg R; Aggarwal M; Mohammad D; Halloran B; Kochhar GS; Todorowski H; Ud Din NM; Izanec J; Teeple A; Gasink C; Muser E; Ding Z; Swaminath A; Lakhani K; Hogan D; Datta S; Ungaro RC; Boland BS; Bohm M; Fischer M; Sagi S; Afzali A; Ullman T; Lawlor G; Baumgart DC; Chang S; Hudesman D; Lukin D; Scherl EJ; Colombel JF; Sands BE; Siegel CA; Regueiro M; Sandborn WJ; Bruining D; Kane S; Loftus EV; Dulai PS
Am J Gastroenterol; 2023 Feb; 118(2):317-328. PubMed ID: 36191274
[TBL] [Abstract][Full Text] [Related]
33. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
[TBL] [Abstract][Full Text] [Related]
36. Safety and Effectiveness of Ustekinumab for Crohn's Disease With Perianal Manifestations: Ad hoc Analysis Data From 1-Year Post-Marketing Surveillance Study in Japan.
Nagano K; Tsuchiya H; Asano T; Yamazaki H; Tominaga S; Matsumoto T
Crohns Colitis 360; 2024 Apr; 6(2):otae035. PubMed ID: 38827168
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
[TBL] [Abstract][Full Text] [Related]
38. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
[TBL] [Abstract][Full Text] [Related]
40. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
